Dylan Morris

Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA.

Dyno Therapeutics, Inc. engages in the development of therapeutics technologies. It develops technologies for safe, efficient and targeted in vivo delivery of new gene therapies and genome editing therapies. The company was founded by Kelsic Eric David and is headquartered in Watertown, MA.

Unlearn.AI, Inc. develops machine learning technology for clinical drug trails. It offers clinical trial design, synthetic control arms, and super-powered subgroup analysis. The company was founded by Aaron Smith, Charles K. Fisher, and Jonathan Walsh in 2017 and is headquartered in San Francisco, CA.

ArrePath, Inc. is an anti-infective drug discovery company that focuses on addressing the health challenge of drug-resistant infections. The platform's proof-of-concept has been demonstrated in studies published in Cell by ArrePath's scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is based in Princeton, NJ, and is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor'easter Ventures. The company utilizes a proprietary machine learning-based platform to efficiently identify anti-infective agents with new mechanisms of action at the outset of the discovery process. This is achieved through a deep understanding and analysis of pathogen behavior. The CEO of the company is Lloyd J. Payne.

Vecprobio Inc. develops manufacturing technologies and tools for gene therapy. The company is based in San Diego, CA. The company was founded in 2022. Daniel Gibbs has been the CEO of the company since 2022.

Insight Venture Management LLC (Insight Venture Partners) is a private equity and venture capital firm, a subsidiary of Insight Holdings Group LLC founded in 1995 by Jeffrey L. Horing and Jerry Fred Murdock. The firm is headquartered in New York.

Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope.

DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022.

Capacity Bio, Inc. is a biotech company based in an undisclosed location. The American company is focused on developing a first-in-class mitophagy therapeutic platform and an advanced analytical toolkit to characterize mitochondria. The company was founded by Amy Wang, Stan Louie, and Kathy Rodgers, and the CEO is Kenneth Nicholas Horne.